Serum level of soluble interleukin‐2 receptor is positively correlated with metabolic tumor volume on 18 F‐FDG PET/CT in newly diagnosed patients with diffuse large B‐cell lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Serum level of soluble interleukin‐2 receptor is positively correlated with metabolic tumor volume on 18 F‐FDG PET/CT in newly diagnosed patients with diffuse large B‐cell lymphoma

Published:2019-02-20 Issue:3 Volume:8 Page:953-962
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Senjo Hajime¹²^ORCID,Kanaya Minoru¹,Izumiyama Koh¹,Minauchi Koichiro²,Hirata Kenji³,Mori Akio¹,Saito Makoto¹,Tanaka Masanori¹,Iijima Hiroaki⁴,Tsukamoto Eriko⁵,Itoh Kazuo⁶,Ota Shuichi²^ORCID,Morioka Masanobu¹,Hashimoto Daigo⁷,Teshima Takanori⁷,

Affiliation:

1. Department of Hematology Aiiku Hospital Sapporo Japan

2. Department of Hematology Sapporo Hokuyu Hospital Sapporo Japan

3. Department of Nuclear Medicine, Graduate School of Medicine Hokkaido University Sapporo Japan

4. Clinical Research and Medical Innovation Center Hokkaido University Hospital Sapporo Japan

5. Department of Radiology Central CI Clinic Sapporo Japan

6. Department of Radiology Keiyukai Sapporo Hospital Sapporo Japan

7. Department of Hematology, Faculty of Medicine Hokkaido University Sapporo Japan

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.1973

Reference35 articles.

1. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

2. How I treat elderly patients with diffuse large B-cell lymphoma

3. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

4. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study

5. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Low echogenicity of Hashimoto's disease could be useful in detecting early phase of thyroid lymphomas, especially diffuse large B cell lymphomas;Thyroid Science;2024-11

2. Real-world applicability of the International Metabolic Prognostic Index in DLBCL: a validation cohort study;Blood Advances;2024-04-11

3. Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma;Journal of Clinical and Experimental Hematopathology;2023-12-26

4. Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy;Scientific Reports;2023-08-22

5. Quantitative PET-based biomarkers in lymphoma: getting ready for primetime;Nature Reviews Clinical Oncology;2023-07-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3